RNASET2 and neoplasm: Considering a recent report pointing at RNASET2 as a candidate biomarker for low vs. high-grade PCa [40], we chose two cell lines (PC-3 and 22Rv1) representing poorly and highly aggressive forms of this tumor type, respectively, to investigate putative differences in their response to RNASET2 modulation.